Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled trial

被引:105
|
作者
van de Wall, Bryan J. M. [1 ]
Stam, Marguerite A. W. [1 ]
Draaisma, Werner A. [1 ]
Stellato, R. [2 ]
Bemelman, Willem A. [3 ]
Boermeester, Marja A. [3 ]
Broeders, Ivo A. M. J. [1 ]
Belgers, Eric J. [4 ]
Toorenvliet, Boudewijn R. [5 ]
Prins, Hubert A. [6 ]
Consten, Esther C. J. [1 ]
机构
[1] Meander Med Ctr, Dept Surg, NL-3813 TZ Amersfoort, Netherlands
[2] Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[3] Acad Med Ctr, Dept Surg, Amsterdam, Netherlands
[4] Atrium Med Ctr, Dept Surg, Heerlen, Netherlands
[5] Ikazia Hosp, Dept Surg, Rotterdam, Netherlands
[6] Jeroen Bosch Hosp, Dept Surg, Den Bosch, Netherlands
来源
关键词
QUALITY-OF-LIFE; IRRITABLE-BOWEL-SYNDROME; DISEASE; CLASSIFICATION; MESALAMINE; DIAGNOSIS; CONSENSUS; RISK;
D O I
10.1016/S2468-1253(16)30109-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Patients with recurrent or persisting complaints after an episode of left-sided diverticulitis are managed with either conservative measures or elective sigmoidectomy. To date, there are no data from randomised trials. We aimed to establish which treatment leads to a better quality of life for patients with diverticulitis. Methods We did an open-label, multicentre, randomised controlled trial (DIRECT trial) in 24 teaching and two academic hospitals in the Netherlands. Patients aged 18-75 years presenting with either recurrent (three or more presentations with clinical signs of acute diverticulitis within 2 years) or persistent abdominal complaints (ongoing lower left abdominal pain or persistent change in bowel habits for >= 3 months) after an episode of left-sided diverticulitis, confirmed by CT, ultrasound, or endoscopy, were included. Patients were excluded if they had previous elective or emergency surgery for acute sigmoid diverticulitis, an absolute operation indication, suspicion of a colorectal malignancy, with a preoperative or postoperative risk greater than III (on the American Society of Anesthesiologists classification), or were unable to complete questionnaire or follow-up. Patients were randomly assigned (3: 3) to receive conservative management or elective (laparoscopic) sigmoidectomy using a digital randomisation system, stratified by type of disease and centre, with a block size of six. Patients, physicians, and researchers were not masked to treatment allocation. Our primary endpoint was health-related quality of life, measured by the Gastrointestinal Quality of Life Index (GIQLI) at 6 months after inclusion or surgery, depending on randomisation group. This trial is registered with trialregister.nl, number NTR1478, and is closed for inclusion. Findings Between July 1, 2010, and April 1, 2014, we randomly assigned 109 patients to receive surgical treatment (resection; n=53) or conservative management (n=56), after which the Data Safety and Monitoring Board prematurely terminated the trial because of increasing difficulties in recruitment. 47 (89%) of 53 patients received surgical treatment and 43 (77%) of 56 patients received conservative management. The GIQLI score at 6 months' follow-up was significantly higher in patients randomly assigned to receive surgical treatment (mean 114.4 [SD 22.3]) than conservative management (100.4 [22.7]; mean difference 14.2, 95% CI 7.2-21 . 1, p<0.0001). 43 (38%) of 109 patients had a severe adverse event in the first 6 months after treatment (18 [34%] of 53 patients in the surgical treatment group vs 23 [40%] of 57 patients in the conservative treatment group). Seven (15%) patients who received surgical treatment developed anastomotic leakage. Of the 56 patients assigned to be treated conservatively, 13 (23%) ultimately underwent elective resection due to ongoing abdominal complaints, with no anastomotic leakage. We recorded no patient deaths. Interpretation Elective sigmoidectomy, despite its inherent risk of complications, results in better quality of life than conservative management in patients with recurrent and persisting abdominal complaints after an episode of diverticulitis.
引用
收藏
页码:13 / 22
页数:10
相关论文
共 50 条
  • [41] A multicentre, randomised, open-label, controlled trial evaluating equivalence of inhalational and intravenous anaesthesia during elective craniotomy
    Citerio, Giuseppe
    Pesenti, Antonio
    Latini, Roberto
    Masson, Serge
    Barlera, Simona
    Gaspari, Flavio
    Franzosi, Maria G.
    EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2012, 29 (08) : 371 - 379
  • [42] Effect of robotic versus open pancreaticoduodenectomy on postoperative length of hospital stay and complications for pancreatic head or periampullarytumours: a multicentre, open-label randomised controlled trial
    Liu, Qu
    Li, Mengyang
    Gao, Yuanxing
    Jiang, Tao
    Han, Bing
    Zhao, Guodong
    Lin, Chao
    Lau, Wan Yee
    Zhao, Zhiming
    Liu, Rong
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (05): : 428 - 437
  • [43] Re: Surgical Treatment for Recurrent Bulbar Urethral Stricture: A Randomised Open-Label Superiority Trial of Open Urethroplasty versus Endoscopic Urethrotomy (the OPEN Trial)
    Elliott, Sean P.
    JOURNAL OF UROLOGY, 2021, 205 (05): : 1507 - 1507
  • [44] Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
    Zhang, Li
    Huang, Yan
    Hong, Shaodong
    Yang, Yunpeng
    Yu, Gengsheng
    Jia, Jun
    Peng, Peijian
    Wu, Xuan
    Lin, Qing
    Xi, Xuping
    Peng, Jiewen
    Xu, Mingjun
    Chen, Dongping
    Lu, Xiaojun
    Wang, Rensheng
    Cao, Xiaolong
    Chen, Xiaozhong
    Lin, Zhixiong
    Xiong, Jianping
    Lin, Qin
    Xie, Conghua
    Li, Zhihua
    Pan, Jianji
    Li, Jingao
    Wu, Shixiu
    Lian, Yingni
    Yang, Quanlie
    Zhao, Chong
    LANCET, 2016, 388 (10054): : 1883 - 1892
  • [45] Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
    Hirsch, L.
    Le Tourneau, C.
    ONCOLOGIE, 2017, 19 (1-2) : 44 - 46
  • [46] Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial
    Abu Dayyeh, Barham K.
    Maselli, Daniel B.
    Rapaka, Babusai
    Lavin, Thomas
    Noar, Mark
    Hussan, Hisham
    Chapman, Christopher G.
    Popov, Violeta
    Jirapinyo, Pichamol
    Acosta, Andres
    Vargas, Eric J.
    Storm, Andrew C.
    Bazerbachi, Fateh
    Ryou, Marvin
    French, Matthew
    Noria, Sabrena
    Molina, Daniel
    Thompson, Christopher C.
    LANCET, 2021, 398 (10315): : 1965 - 1973
  • [47] Intravenous remifentanil patient-controlled analgesia versus intramuscular pethidine for pain relief in labour (RESPITE): an open-label, multicentre, randomised controlled trial
    Wilson, Matthew J. A.
    MacArthur, Christine
    Hewitt, Catherine A.
    Handley, Kelly
    Gao, Fang
    Beeson, Leanne
    Daniels, Jane
    LANCET, 2018, 392 (10148): : 662 - 672
  • [48] Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial (vol 12, pg 344, 2011)
    van Hooft, J. E.
    Bemelman, W. A.
    Oldenburg, B.
    LANCET ONCOLOGY, 2011, 12 (05): : 418 - 418
  • [49] Minimally invasive surgery versus open surgery in the treatment of lumbar spondylolisthesis: study protocol of a multicentre, randomised controlled trial (MISOS trial)
    Arts, Mark P.
    Wolfs, Jasper F. C.
    Kuijlen, Jos M. A.
    de Ruiter, Godard C. W.
    BMJ OPEN, 2017, 7 (11):
  • [50] Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care
    Shah, Pallav L.
    Orton, Christopher M.
    Grinsztejn, Beatriz
    Donaldson, Gavin C.
    Ramirez, Brenda Crabtree
    Tonkin, James
    Santos, Breno R.
    Cardoso, Sandra W.
    Ritchie, Andrew, I
    Conway, Francesca
    Riberio, Maria P. D.
    Wiseman, Dexter J.
    Tana, Anand
    Vijayakumar, Bavithra
    Caneja, Cielito
    Leaper, Craig
    Mann, Bobby
    Samson, Anda
    Bhavsar, Pankaj K.
    Boffito, Marta
    Johnson, Mark R.
    Pozniak, Anton
    Pelly, Michael
    LANCET RESPIRATORY MEDICINE, 2023, 11 (05): : 415 - 424